BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12611072)

  • 1. Targeting CD19 with genetically modified EBV-specific human T lymphocytes.
    Roessig C; Scherer SP; Baer A; Vormoor J; Rooney CM; Brenner MK; Juergens H
    Ann Hematol; 2002; 81 Suppl 2():S42-3. PubMed ID: 12611072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy.
    Pizzitola I; Agostoni V; Cribioli E; Pule M; Rousseau R; Finney H; Lawson A; Biondi A; Biagi E; Marin V
    J Immunother; 2011; 34(6):469-79. PubMed ID: 21654519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
    Cooper LJ; Al-Kadhimi Z; DiGiusto D; Kalos M; Colcher D; Raubitschek A; Forman SJ; Jensen MC
    Blood Cells Mol Dis; 2004; 33(1):83-9. PubMed ID: 15223016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
    Marin V; Dander E; Biagi E; Introna M; Fazio G; Biondi A; D'Amico G
    Exp Hematol; 2006 Sep; 34(9):1219-29. PubMed ID: 16939815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
    Cheadle EJ; Hawkins RE; Batha H; O'Neill AL; Dovedi SJ; Gilham DE
    J Immunol; 2010 Feb; 184(4):1885-96. PubMed ID: 20089697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive cellular immunotherapy with CD19-specific T cells.
    Rössig C; Pscherer S; Landmeier S; Altvater B; Jürgens H; Vormoor J
    Klin Padiatr; 2005; 217(6):351-6. PubMed ID: 16307422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
    Arakawa F; Shibaguchi H; Xu Z; Kuroki M
    Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
    Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.
    Numbenjapon T; Serrano LM; Chang WC; Forman SJ; Jensen MC; Cooper LJ
    Exp Hematol; 2007 Jul; 35(7):1083-90. PubMed ID: 17588477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
    Gonzalez S; Naranjo A; Serrano LM; Chang WC; Wright CL; Jensen MC
    J Gene Med; 2004 Jun; 6(6):704-11. PubMed ID: 15170741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
    J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.
    Rossig C; Bollard CM; Nuchtern JG; Rooney CM; Brenner MK
    Blood; 2002 Mar; 99(6):2009-16. PubMed ID: 11877273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
    Singh H; Serrano LM; Pfeiffer T; Olivares S; McNamara G; Smith DD; Al-Kadhimi Z; Forman SJ; Gillies SD; Jensen MC; Colcher D; Raubitschek A; Cooper LJ
    Cancer Res; 2007 Mar; 67(6):2872-80. PubMed ID: 17363611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.